相关实验视频

Updated: May 2, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

对于卵巢癌复发和一线维持治疗的二次细胞削减手术:一个多中心的回顾性研究

Stefano Uccella¹, Andrea Puppo², Simone Garzon¹

¹Unit of Gynecology and Obstetrics, Department of Surgery, Dentistry, Pediatrics, and Gynecology, University of Verona, AOUI Verona, Verona, Italy.

European journal of obstetrics, gynecology, and reproductive biology

|February 23, 2025

概括

在卵巢癌复发的二次手术中进行完整的细胞缩小是生存的关键. 一线维护疗法,如贝瓦西祖马布或PARP抑制剂可能会影响结果,但不会影响手术的安全性.

科学领域:

妇科瘤学妇科瘤学
手术瘤学手术瘤学
卵巢癌研究研究卵巢癌研究

背景情况:

卵巢癌复发通常需要进行二次细胞减小手术.
之前一线维持治疗对二次手术结果的影响尚未完全理解.

研究的目的:

为了评估复发性卵巢癌的二次细胞削减手术的外科和瘤结果.
评估先前一线维持治疗对这些结果的影响.

主要方法:

在意大利三个中心 (1997-2022) 进行了对189名因卵巢癌复发而接受二次细胞减小手术的患者的回顾性分析.
收集的数据包括临床,手术,病理特征,以及新辅助,辅助和维持疗法的细节.
从前性收集的数据库和医疗记录中检索后续信息.

主要成果:

在75%的患者中实现了完整的细胞减少,并且是无进展和因果特定生存的最强预测指标.
以前的第一线维护疗法没有影响完整细胞减少率或术后并发症的发生率.
第一线贝瓦西祖马布和PARP抑制剂与某些亚组的无进展生存率较差有关,而第二线维持疗法改善了生存率.

结论:

在二次手术期间进行完整的细胞缩小是卵巢癌复发的最关键的预后因素.
第一线维护疗法不会影响二次细胞减少的安全性或可行性.
虽然没有影响手术结果,但一线维持疗法可能会影响二次手术后的整体预后.

关键词:

贝瓦西祖马布 (bevacizumab) 是一种药物.卵巢癌是发生在卵巢中的癌症.在 PARP 抑制剂.外科手术期间的并发症.复发情况复发情况二次手术是第二次手术.

更多相关视频

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma

Published on: January 22, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...